Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD
Season 13, Episode 3, May 19, 09:05 PM
Share
Subscribe
Dr Mauro discusses ways that the newest formulation of nilotinib for Ph-positive CML addresses treatment adherence issues by reducing the need for fasting.
In today’s episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.
In our exclusive interview, Dr Mauro discussed barriers to nilotinib treatment adherence in patients with Ph-positive CML, ways that nonadherence can diminish quality of life and clinical response to treatment, ways that the new formulation of nilotinib addresses adherence issues by reducing the need for fasting, and ongoing research into alternative formulations of other agents that may further improve CML treatment efficacy and tolerability.
In our exclusive interview, Dr Mauro discussed barriers to nilotinib treatment adherence in patients with Ph-positive CML, ways that nonadherence can diminish quality of life and clinical response to treatment, ways that the new formulation of nilotinib addresses adherence issues by reducing the need for fasting, and ongoing research into alternative formulations of other agents that may further improve CML treatment efficacy and tolerability.